These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8193425)

  • 21. A comparison of clinical outcome studies among cholesterol-lowering agents.
    Lousberg TR; Denham AM; Rasmussen JR
    Ann Pharmacother; 2001 Dec; 35(12):1599-607. PubMed ID: 11793629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
    Bjelajac A; Goo AK; Weart CW
    Ann Pharmacother; 1996 Nov; 30(11):1304-15. PubMed ID: 8913414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapy for lipid disorders. Selecting appropriate lipid-lowering agents.
    LaRosa JC
    Postgrad Med; 1987 Jul; 82(1):103-11. PubMed ID: 3601832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lipoprotein (a)--a mysterious factor in atherogenesis].
    Jelaković B; Laganović M; Kuzmanić D
    Lijec Vjesn; 2002; 124(11-12):366-71. PubMed ID: 12679978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
    Backes JM; Gibson CA
    Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperlipoproteinemia(a): clinical significance and treatment options.
    Berthold HK; Gouni-Berthold I
    Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
    Saika Y; Kodama N; Kimura K; Fujii R; Ohtani H; Mune M; Mimura K; Maeda T; Yukawa S
    Nihon Jinzo Gakkai Shi; 1999 Jun; 41(4):430-5. PubMed ID: 10441992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.
    Anagnostis P; Karras S; Lambrinoudaki I; Stevenson JC; Goulis DG
    Int J Clin Pract; 2016 Dec; 70(12):967-977. PubMed ID: 28032426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein(a) as a therapeutic target in cardiovascular disease.
    Koschinsky M; Boffa M
    Expert Opin Ther Targets; 2014 Jul; 18(7):747-57. PubMed ID: 24848373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein (a): perspectives from a lipid-referral program.
    Rubenfire M; Vodnala D; Krishnan SM; Bard RL; Jackson EA; Giacherio D; Brook RD
    J Clin Lipidol; 2012; 6(1):66-73. PubMed ID: 22264576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
    Brunetti L; Hermes-Desantis ER
    Ann Pharmacother; 2010; 44(7-8):1196-206. PubMed ID: 20551301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
    Chin-Dusting JP; Shaw JA
    Expert Opin Pharmacother; 2001 Mar; 2(3):419-30. PubMed ID: 11336596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.